Obesity drug coverage cuts

Insurance plans are cutting back coverage for obesity drugs, leaving millions of Americans to pay cash, switch medicines, or stop treatment. (goodrx.com) GoodRx said on March 31 that more than 41 million people with commercial insurance lacked coverage for Wegovy in 2026, up 42% from 2025, and more than 109 million lacked coverage for Zepbound, up 12%. Those shifts translate to roughly 12 million more people losing Wegovy coverage and about 12 million more losing Zepbound coverage in a year. (goodrx.com) The pullback is hitting drugs that are prescribed for long-term weight management, not short courses. Wegovy is approved for chronic weight management and, since March 2024, to cut the risk of heart attack, stroke, and cardiovascular death in some adults with obesity or overweight and heart disease; Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity. (fda.gov, fda.gov, fda.gov) Coverage has long been patchy because obesity treatment sits in a different insurance bucket than diabetes care. Kaiser Family Foundation said in January that only 13 state Medicaid fee-for-service programs covered GLP-1 drugs for obesity treatment, most large employers still limited coverage, and Medicare generally could not cover these drugs for obesity under existing law. (kff.org) Federal policy is starting to shift, but slowly and unevenly. The Centers for Medicare & Medicaid Services said a temporary Medicare GLP-1 Bridge will begin July 1, 2026 outside Part D, and a broader BALANCE model is set to start in Medicaid in 2026 and Medicare in 2027. (cms.gov, cms.gov, cms.gov) For patients losing coverage now, the fallback is often manufacturer discount programs rather than insurance. NovoCare says eligible cash-paying patients can get Wegovy for $349 a month after June 30, 2026, while Lilly says eligible commercially insured patients whose plans do not cover Zepbound can start at $299 for a one-month KwikPen prescription. (novocare.com, zepbound.lilly.com) Drugmakers are also trying to widen access through direct sales and new products. Novo Nordisk announced on Feb. 24 that it would cut U.S. list prices for Wegovy, Ozempic, and Rybelsus, and on March 31 launched a multi-month Wegovy subscription program; the Food and Drug Administration approved a higher-dose Wegovy HD on March 19. (novonordisk-us.com, fda.gov) Even with those discounts, out-of-pocket demand has kept rising. GoodRx reported on March 31 that fills for weight-loss medicines such as semaglutide and tirzepatide were still climbing despite high cash prices and tighter insurance rules. (goodrx.com) The immediate result is that access depends less on a prescription than on the fine print of a health plan. Until broader public coverage starts in mid-2026 and 2027, many patients will keep making month-to-month decisions about whether they can stay on the medicines at all. (cms.gov, cms.gov, goodrx.com)